National Clinical Audit of Psychosis (NCAP) Audit of practice form. Notes for completion

Similar documents
Mental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service

Treatment of Schizophrenia Appendix Three Page 1 of 8

AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Document Title Antipsychotics Prescribing Guidelines for Schizophrenia

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]

High Dose Antipsychotic Therapy (HDAT) guideline

Antipsychotic Prescribing Audit:

Choosing and delivering ering interventions entions for

National Audit of Psychological Therapies (NAPT) Retrospective case record audit data set

High Dose Antipsychotic Therapy (HDAT) guideline

Prescription of High Dose Antipsychotic Medication

MMG012 GUIDELINES FOR THE USE OF HIGH DOSE ANTIPSYCHOTIC MEDICATION

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Formulary Item Restrictions and/or Advice Site availability

Psychosis & Schizophrenia: The Updated NICE Quality Standard. Dr Tony Gill Mental Health Practitioner University of Leeds 7 th June 2015

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES

SHARED CARE GUIDELINE

This factsheet covers:

Smoking cessation interventions and services

GLP-1 Initiation and Follow Up. Version Date Summary of Changes 1.0 April 2013 This is a new template

Mental Health Clinical Pathways Group. The Case for Change

NAS NATIONAL AUDIT OF SCHIZOPHRENIA. Second National Audit of Schizophrenia What you need to know

Worcestershire Dementia Strategy

Clinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents

Preferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses

Michael J. Bailey, M.D. OptumHealth Public Sector

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE. Type 2 diabetes: the management of type 2 diabetes (update)

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine

Antipsychotics. This factsheet covers -

Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

Physical health of those with serious mental illness.

National Clinical Audit of Psychosis. National report for the core audit

Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit

Why are NICE guidelines and standards important and relevant to us?

Risk assessment for type 2 diabetes

Clinical guideline Published: 12 February 2014 nice.org.uk/guidance/cg178

How Good a Doctor? Physical Health Care in a Forensic Setting. Dr. Alan Cohen FRCGP

NHS Grampian Guidance For Staff Working In The Mental Health Service For The Use Of High-Dose Antipsychotic Medication

IDDT Fidelity Action Planning Guidelines

Clinical guideline Published: 23 January 2013 nice.org.uk/guidance/cg155

Early Intervention Teams services for early psychosis

High Dose Antipsychotic Medication Policy

Schizophrenia: core interventions in the treatment and management of schizophrenia

HIGH DOSE ANTIPSYCHOTIC GUIDELINES (HDAT)

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)

1. THE NEW ACCESS & WAITING TIME

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Standard Operating Procedure: Early Intervention in Psychosis Access Times

The treatment of bipolar disorder in adults, children and adolescents

University of Groningen. Metabolic risk in people with psychotic disorders Bruins, Jojanneke

National NHS patient survey programme Survey of people who use community mental health services 2014

Guideline for use of Intramuscular Medication for Acutely Disturbed Behaviour in Mental Health and Associated Services

Safe transfer of prescribing guidance

Stop Smoking Service Client Record Form 1

Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

Achieve. Salford Young People s Service. Salford Recovery

Dr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead

Conor K Farren. St Patricks University Hospital Trinity College Dublin Ireland

2010 National Audit of Dementia (Care in General Hospitals) North West London Hospitals NHS Trust

EARLY ONSET SCHIZOPHRENIA

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Taking Care: Child and Youth Mental Health PSYCHOSIS TREATMENT OPTIONS

Hypertension Clinical case scenarios for primary care

Additional details about you What is your ethnic group? Name of next of kin \ Emergency contact

Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014)

Conway PMS. NHS Health Check Questionnaire

Somerset Phoenix Project: Self-request for support

Aggression (Severe) in Children under Age 6

SERVICE USER INFORMATION

Aiming for recovery for patients with severe or persistent depression a view from secondary care. Chrisvan Koen

2010 National Audit of Dementia (Care in General Hospitals) Chelsea and Westminster Hospital NHS Foundation Trust

Medication Management. Dr Ajith Weeraman MBBS, MD (Psychiatry), FRANZCP Consultant Psychiatrist Epworth Clinic Camberwell 14 th March 2015

Proposed Changes to Existing Measure for HEDIS : Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)

Class Update: Oral Antipsychotics

2010 National Audit of Dementia (Care in General Hospitals) Guy's and St Thomas' NHS Foundation Trust

Document Title Pharmacological Management of Generalised Anxiety Disorder

Minimising the Impact of Medication on Physical Health in Schizophrenia

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Somerset Phoenix Project: Parent/Carer request for support

Use of antipsychotic medication in people with a learning disability

MEDICINES MANAGEMENT TOOL FOR ANTIPSYCHOTICS

ESSENTIAL SHARED CAR E AGREEMENT FOR

Physical Health Checks

The links between physical health in mental health

CEPP National Audit Antipsychotics in Dementia

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)

GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA)

DRAFT. Consultees are asked to consider and comment on the CEPP National Audit: Antipsychotics in Dementia document.

Mental Health Review

Prescribing medications for people with a personality disorder A service evaluation of a community mental health team

Transcription:

National Clinical Audit of Psychosis (NCAP) Audit of practice form tes for completion Audit forms should be completed by the psychiatrist accountable for the patient's care If delegated, the psychiatrist accountable for the patient's care must confirm the data are correct Please complete a separate audit form for each patient Your audit lead will tell you which of your patients have been selected Patients have been randomly selected from all patients in your Trust/Health Board who meet the criteria for NCAP It is essential that you do not make your own selection of which patient to audit How to complete this audit form All data must be collected by 31 October 2017 and submitted online by 29 vember 2017 Please contact your local audit lead if you are unsure how this is being managed in your Trust/Health Board Audit forms should be completed using information from the paper and/or electronic case records and clinical knowledge of the patient There may be items for which you need to speak to a member of clinical staff who has known the patient for a longer period than yourself, eg a CPN, Consultant Psychiatrist or a Staff Grade Psychiatrist from the relevant clinical team All questions are mandatory Further assistance and information Please contact your local audit lead in the first instance You may also contact the central NCAP Team on NCAP@rcpsychacuk or 020 3701 2602/2756 or visit our website at wwwrcpsychacuk/ncap Your local NCAP audit lead is: The NCAP ID for your organisation is: NCAP Patient ID* (to be completed by local NCAP audit lead): (Number 1-n, assigned by local audit lead for local tracking purposes) Initials of data collector/clinician: Page 1 of 17

Section A: Clinical team and patient status Q1a Clinical team currently* responsible for the patient's care (*refers to the clinical team responsible for the patient's care on the audit census date 1 July 2017) (Please note EIP patients are excluded from this audit; see guidance notes) The patient is currently an inpatient For fewer than 7 nights For 7 or more nights Assertive Outreach Team Community Mental Health Team Crisis Resolution/Home Treatment Team Other clinical team* *please specify Q1b If the patient is not currently an inpatient, has this patient been an inpatient in the last 12 months?, for 7 or more nights, for fewer than 7 nights Q1c Is this patient currently under a Care Program Approach or equivalent if outside England? (see guidance notes) Q1d Is this patient subject to a Community Treatment Order (CTO)? Q2 From which Clinical Commissioning Group (CCG) (in England) or District (in Wales) does this patient originate? (see guidance notes) Page 2 of 17

Section B: Patient details Q3 Year of birth (YYYY): Y Y Y Y Q4 Gender: Q5 Ethnicity: White Black or Black British Male Female Other/undefined Asian or Asian British Mixed Other ethnic groups British African Bangladeshi Asian & White Chinese Irish Caribbean Indian Black African & White Any other ethnic background Any other White background Any other Black background Pakistani Black Caribbean & White t documented Any other Asian background Any other Mixed background t stated/refused Q6 Current ICD-10 mental heath diagnosis: (select one option only) F10-19/xx5 Persistent substance-induced psychosis F22 Persistent delusional disorder F20 Schizophrenia F24 Induced delusional disorder F28/29 Other unspecified F25 Schizoaffective disorder non-organic psychosis Q7 Was this diagnosis made in the last three years? Section C: Patient's current mental health Q8 Please use your knowledge of the patient to rate the patient's current mental health: Please keep a note of your answer as this information will be needed later in Section E (select one option only) 1 = Full remission 2 = Partial remission with minimal symptoms and disability 3 = Partial remission with substantial symptoms and/or disability 4 = t in remission Page 3 of 17

Q9a Has a Health of the Nation Outcomes Scale (HoNOS) been completed for this patient in the last 12 months? Q9b If yes to Q9a above, please complete the HoNOS items below from the most recent HoNOS assessment available for the patient: (Scores from >12 months ago are deemed ineligible; a glossary for Hos is available at wwwrcpsychacuk/ncap/resources) 0 1 2 3 4 9 (t known) 1 Overactive, aggressive, disruptive or agitated behaviour 2 n-accidental self-injury 3 Problem drinking or drug-taking 4 Cognitive problems 5 Physical illness or disability problems 6 Problems associated with hallucinations and delusions 7 Problems with depressed mood 8 Other mental and behavioural problems 9 Problems with relationships 10 Problems with activities of daily living 11 Problems with living conditions 12 Problems with occupation and activities 0 = problem 1 = Minor problem requiring no action 2 = Mild problem but definitely present 3 = Moderately severe problem 4 = Severe to very severe problem Section D: Regular antipsychotic medication(s) Q10 What is this patient's history of prescription of regular (NOT PRN) antipsychotic medication? Patient has never been prescribed an antipsychotic (go to Section E) Patient has previously been prescribed antipsychotic medication but is not currently prescribed an antipsychotic (go to Section E) Patient is currently prescribed an antipsychotic (go to Q11) Page 4 of 17

The next two questions ask for information on names and doses of regular (NOT PRN) antipsychotic medications prescribed Please record oral/long-acting injection (LAI/depot) medications separately, in the appropriate questions Please do not record information on doses of short acting intra-muscular (IM) injections as these are different from LAI/depot medications Q11 Please provide the current dose of the all oral antipsychotics currently being regularly prescribed for the patient (DO NOT INCLUDE ANY ANTIPSYCHOTICS PRESCRIBED PRN) If a medication is documented as mcg (micrograms), please make sure that this is converted and entered correctly as mg for the purposes of this audit For example, 250mcg should be entered on the audit tool as 025mg Amisulpride regular oral daily mg Aripiprazole regular oral daily mg Asenapine regular oral daily mg Benperidol regular oral daily mg Chlorpromazine regular oral daily mg Clozapine regular oral daily mg Flupentixol regular oral daily mg Haloperidol regular oral daily mg Levomepromazine regular oral daily mg Lurasidone regular oral daily mg Olanzapine regular oral daily mg Paliperidone Regular oral daily mg Pericyazine regular oral daily mg Perphenazine regular oral daily mg Pimozide regular oral daily mg Promazine regular oral daily mg Quetiapine regular oral daily mg Risperidone regular oral daily mg Sertindole regular oral daily mg Sulpiride regular oral daily mg Trifluoperazine regular oral daily mg Zotepine regular oral daily mg Zuclopenthixol regular oral daily mg Other antipsychotic name: regular oral daily mg dose Page 5 of 17

Q12 Please provide the current dose of all long-acting injection/depot antipsychotics currently being regularly prescribed for the patient (DO NOT INCLUDE ANY LONG-ACTING INJECTION OR DEPOT ANTIPSYCHOTICS PRESCRIBED AS A SINGLE OR TEST DOSE) Please enter all regular long-acting injection (LAI) or depot injection doses as weekly doses eg a 300mg dose of Fluphenazine once every 2 weeks would be entered as 150mg of Fluphenazine per week Aripiprazole (long-acting) mg/week Flupentixol (depot) mg/week Fluphenazine (depot) mg/week Haloperidol (depot) mg/week Olanzapine (long-acting) mg/week Paliperidone (long-acting) mg/week Risperidone (long-acting) mg/week Zuclopenthixol (depot) mg/week Other depot/lai antipsychotic name: mg/week dose: Q13a Is the patient currently being regularly prescribed two or more antipsychotic drugs at the same time? Q13b If yes to Q13a above, has a clear rationale for this been documented in the patient's records? Q14a Is the patient's total current regular antipsychotic dose, taking all of their regular antipsychotic medications into account, above 100% of the BNF recommended dose limits for the medications? Page 6 of 17

Q14b If yes to Q14a, has a clear rationale for this been documented in the patient's records? Q15 Is there documented evidence that the benefits and side-effects of the antipsychotic medication currently regularly prescribed were discussed with the patient? Q16 For the antipsychotic currently regularly prescribed, is there documented evidence that the patient was involved in deciding which antipsychotic medication they were prescribed? Q17 Is there documented evidence that the patient was provided with written information (or an appropriate alternative) about the antipsychotic medication currently regularly prescribed? Section E: Further history of management for patients not in remission or only in partial remission with substantial symptoms (whether or not on clozapine) Answer Q18-21 (Section E) if the patient is either currently not in remission or is only in partial remission with substantial symptoms and disability, as indicated by a response of '3' or '4' to Question 8 If the patient is in remission or in partial remission with minimal symptoms, as indicated by a response of '1' or '2' to Question 8, then go directly to Section F Q18 Is there documented evidence that in the past 12 months, medication adherence has been investigated as a potential cause of inadequate response to current antipsychotic medication? Q19 Is there documented evidence that in the past 12 months, alcohol or substance misuse have been investigated as a potential cause of inadequate response to current antipsychotic medication? Page 7 of 17

Q20 Is the current regular antipsychotic medication being prescribed at an optimum dose*? (*optimal dose: between 75% and 100% of BNF maximum dose or lower if side effects preclude further dose increase) Q21a Is the patient currently being prescribed clozapine? (go to Q22) Q21b Please indicate the reason(s) why this patient is not currently prescribed clozapine? (tick all that apply) reason(s) indicated t yet had adequate trial of two other other antipsychotics Unable to determine whether other antipsychotic doses are inadequate Clozapine is medically contraindicated for this patient Clozapine previously tried, patient did not respond adequately or had undue adverse effects Clozapine offered but patient refused Ongoing anxiety and depression but not psychotic symptoms Currently experiencing a relapse that is expected to be short-term Trust/Health Board restrictions on use of clozapine Waiting for an inpatient bed in order to be able to initiate clozapine Lack of service for community initiation Clozapine not commenced because of fears of poor compliance with treatment Clozapine not commenced because of fears about abuse of alcohol or other substances Other* *please specify Page 8 of 17

Section F: Physical Health monitoring For Q22-38 we would like to know what physical health monitoring has been undertaken and is recorded in the Trust/Health Board case record for the patient Q22 Has the patient been offered lifestyle advice on diet and physical activity? Q23 Does the patient currently have any of the following significant physical health problems and is this recorded in their case records? Cardiovascular disease Recorded diagnosis Diagnosis but not recorded Recorded as no problem present record but known not to have problem t known Diabetes Hypertension Dyslipidaemia Q24 Does the patient have a Family History (1st degree relatives only) of any of the following significant health problems and is this recorded in their case records? Cardiovascular disease (first diagnosed under 60 years) record Diabetes Hypertension Dyslipidaemia Page 9 of 17

Q25 Smoking status Current smoker ---> Ex-smoker or non-smoker t documented SCREENING Optional: number of cigarettes smoked per day: Documented evidence of refusal to provide information on more than one occasion after it is assured that the person has been given the information on which to make an informed decision Q26 Alcohol consumption ---> Harmful or hazardous use of alcohol Alcohol use that is NOT harmful or hazardous t documented Documented evidence of refusal to provide information on more than one occasion after it is assured that the person has been given the information on which to make an informed decision Q26 guidance: Identification of harmful or hazardous use of alcohol is described in NICE guideline CG115 http://wwwniceorguk/guidance/cg115 It may be assessed using structured measures such as the 'AUDIT' or based on enquiring about quantity, frequency and any health or social consequences of alcohol consumption Where there is a record of drinking that is neither harmful nor hazardous eg 'rarely drinks'/ 'drinks in moderation' this should be recorded as 'Alcohol use that is NOT harmful or hazardous' Q27 Substance misuse t documented Documented evidence of refusal to provide information on more than one occasion after it is assured that the person has been given the information on which to make an informed decision Page 10 of 17

Q28 BMI/Weight Is information about weight recorded in the patient's notes? (please enter at least one value below) t documented Documented evidence of refusal to be weighed/measured on more than one occasion after it is assured that the person has been given the information on which to make an informed decision Patient was pregnant/gave birth within the last 6 weeks (weight not measured) BMI (Body mass Index) (Kg/m2) and/or Change in weight over a 3 month period: > 5kg < or = 5kg increase Q29 Blood pressure Is information about blood pressure recorded in the patient's notes? (please enter at least one value below) t documented Documented evidence of refusal to take blood pressure on more than one occasion after it is assured that the person has been given the information on which to make an informed decision Systolic (mmhg) and/or Diastolic (mmhg) Q30 Glucose Is information about blood glucose recorded in the patient's notes? (please ensure you use the correct units) (please enter at least one value below) t documented Documented evidence of refusal of blood test when offered on more than one occasion after it is assured the person has been given the information on which to make an informed decision Patient was pregnant/gave birth within the last 6 weeks (glucose screening not carried out) Glycated haemoglobin or HbA1c (mmol/mol) and/or Fasting plasma glucose (mmol/l) and/or Random plasma glucose (mmol/l) Page 11 of 17

Q31 Cholesterol Is information about cholesterol recorded in the patient's notes? (please ensure you use the correct units) (please enter at least one value below) t documented Documented evidence of refusal of blood test when offered on more than one occasion after it is assured that the person has been given the information on which to make an informed decision Total cholesterol (mmol/l) and/or n-hdl cholesterol (mmol/l) and/or QRISK-2 score (%) Q32 Interventions for smoking cessation (see guidance notes) Brief intervention Referral to smoking cessation service Combined NRT (nicotine replacement therapy) and/or varenicline/buproprion Individual/group behavioural support Documented evidence of refusing intervention after it is assured that the person has been given the right information on which to make an informed decision intervention needed t documented Q33 Interventions for harmful alcohol use Brief intervention and advice Motivational interviewing Referral to psycho-education programme Individual/group behavioural support Pharmacological intervention for harmful use of alcohol commenced or reviewed (eg acamprosate, disulfram or naltrexone) Referral to specialist service Documented evidence of refusing intervention after it is assured that the person has been given the right information on which to make an informed decision intervention needed INTERVENTIONS t documented Page 12 of 17

Q34 Interventions for substance misuse Brief intervention/advice Referral to detoxification programme Referral to psycho-education programme Motivational interviewing Referral to specialist service Documented evidence of refusing intervention after it is assured that the person has been given the right information on which to make an informed decision intervention needed t documented Q35 Interventions for weight gain/obesity Mental health medication review with respect to weight (eg antipsychotic) Advice or referral about diet Advice or referral about exercise Referral to structured lifestyle education programme Pharmacological intervention for obesity commenced or reviewed Referral to primary or secondary care physician Documented evidence of refusing intervention after it is assured that the person has been given the right information on which to make an informed decision intervention needed t documented Q36 Interventions for hypertension Mental health medication review with respect to high blood pressure (eg antipsychotic) Advice or referral about diet/salt intake Advice or referral about exercise Anti-hypertensive drug treatment commenced or reviewed Referral to primary or secondary care physician Documented evidence of refusing intervention after it is assured that the person has been given the right information on which to make an informed decision intervention needed as repeat blood pressure test normal intervention needed t documented Page 13 of 17

Q37 Interventions for diabetes/high risk of diabetes Mental health medication review with respect to glucose regulation (eg antipsychotic) Advice or referral about diet Advice or referral about exercise Pharmacotherapy for diabetes commenced or reviewed (eg metformin, insulin, acarbose or exenatide) Referral to structured lifestyle education programme Referral to primary or secondary care physician Documented evidence of refusing intervention after it is assured that the person has been given the right information on which to make an informed decision intervention needed t documented Q38 Interventions for dyslipidemia Mental health medication review to lower blood lipids (eg antipsychotic) Advice or referral about diet Advice or referral about exercise Lipid modification medication (eg statin) Referral to primary or secondary care physician Documented evidence of refusing intervention after it is assured that the person has been given the right information on which to make an informed decision intervention needed t documented Section G: Psychological Therapies Q39 Has the patient been offered Cognitive Behavioural Therapy for Psychosis (CBTp) by a suitably qualified therapist? Please note that the therapist must have postgraduate diploma level or equivalent generic CBT training (in the form of a CBT training programme or in the course of training as a clinical psychologist), plus additional specialised CBTp training (see guidance notes), CBTp In the last 12 months (go to Q42) At some point over the course of their illness (go to Q42) Page 14 of 17

Q40 If '' to Q39, was CBTp by a suitably qualified therapist available? Please note that the therapist must have postgraduate diploma level or equivalent generic CBT training (in the form of a CBT training programme or in the course of training as a clinical psychologist), plus additional specialised CBTp training (see guidance notes) t known Q41a If to Q39, has the patient been offered a form of Cognitive Behavioural Therapy that does not conform to the detailed guidelines laid out by NICE (CG178) and/or was not delivered by someone qualified as a CBTp therapist? (This should NOT include any therapy regarded as one of the following: Counselling and Supportive Therapy, Psychodynamic/Psychoanalytical Therapy, Psychoeducation, Social Skills Training) (go to Q43), CBT In the last 12 months At an earlier stage of their illness Q41b If to Q41a, which type of staff member delivered this therapy? t known Clinical Psychologist Psychiatrist Nurse (Ward nurse, Nurse Consultant, CPN, etc) Social Worker Occupational Therapist Other* *please specify Q42 If CBT/CBTp was offered, was this taken up by the patient?, was taken up t taken up - patient refused t taken up - other reason recorded t taken up - reason not recorded t known Page 15 of 17

Q43 Where the patient is in contact with the family, has Family Intervention (FI) by a suitably qualified therapist been offered to members of the patient's family? Please note that practitioners delivering this approach require specific FI training lasting 5 days or more (See guidance notes) in the last 12 months at an earlier stage of their illness, but was available, as FI was not available N/A, patient not in contact with family N/A, patient refused to allow team to contact family N/A, was not seen as appropriate for this patient Q44 If FI was offered, was this taken up by the patient's family?, was taken up t taken up - patient refused t taken up - family refused t taken up - other reason recorded t taken up - reason not recorded t known Section H: Care plan, employment and carer support Q45 Does the patient have a current care plan? Q46 Does the care plan/crisis plan include details of how to contact services in a crisis? Page 16 of 17

Q47 Employment/education status: (see guidance notes) Employed Unemployed and seeking work Student who is not working or actively seeking work Long-term sick or disabled receiving benefits Homemaker not working or actively seeking work t working or actively seeking work Unpaid voluntary work and not working or actively seeking work Retired t stated Q48 If seeking work (Q47), has the patient been offered any of the following? (tick all that apply; see guidance notes) ne t documented Employment support programme (Individual Placement and Support) Employment support programme (other) Vocational support programme Apprenticeship programme Education programme Other* *please specify Q49 Have the needs of the patient's carer assessment been assessed by mental health services? N/A patient does not have a carer END OF AUDIT FORM Thank you for completing this audit form for this patient Page 17 of 17